Terms: = Ovarian cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790
13 results:
1. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
[TBL] [Abstract] [Full Text] [Related]
2. TET enzymes and 5hmC epigenetic mark: new key players in carcinogenesis and progression in gynecological cancers.
Zacapala-Gómez AE; Mendoza-Catalán MA; Antonio-Véjar V; Jiménez-Wences H; Ortíz-Ortíz J; Ávila-López PA; Baños-Hernández CJ; Salmerón-Bárcenas EG
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):1123-1134. PubMed ID: 38375718
[TBL] [Abstract] [Full Text] [Related]
3. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness.
Chen S; Wu Y; Gao Y; Wu C; Wang Y; Hou C; Ren M; Zhang S; Zhu Q; Zhang J; Yao Y; Huang M; Qi YB; Liu XS; Horng T; Wang H; Ye D; Zhu Z; Zhao S; Fan G
Cell Rep; 2023 Oct; 42(10):113246. PubMed ID: 37831605
[TBL] [Abstract] [Full Text] [Related]
4. Aberrant epigenetic regulation of FZD3 by tet2 is involved in ovarian cancer cell resistance to cisplatin.
Zhu L; Zhou Q
J Chemother; 2024 Apr; 36(2):143-155. PubMed ID: 37300277
[TBL] [Abstract] [Full Text] [Related]
5. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
6. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
Kharat SS; Ding X; Swaminathan D; Suresh A; Singh M; Sengodan SK; Burkett S; Marks H; Pamala C; He Y; Fox SD; Buehler EC; Muegge K; Martin SE; Sharan SK
Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817374
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.
Da Cruz Paula A; da Silva EM; Segura SE; Pareja F; Bi R; Selenica P; Kim SH; Ferrando L; Vahdatinia M; Soslow RA; Vidal A; Gatius S; Przybycin CG; Abu-Rustum NR; Matias-Guiu X; Rubin BP; Reis-Filho JS; DeLair DF; Weigelt B
Mod Pathol; 2020 Aug; 33(8):1606-1617. PubMed ID: 32203090
[TBL] [Abstract] [Full Text] [Related]
8. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract] [Full Text] [Related]
9. Genetic Variants in Epigenetic Pathways and Risks of Multiple cancers in the GAME-ON Consortium.
Toth R; Scherer D; Kelemen LE; Risch A; Hazra A; Balavarca Y; Issa JJ; Moreno V; Eeles RA; Ogino S; Wu X; Ye Y; Hung RJ; Goode EL; Ulrich CM;
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):816-825. PubMed ID: 28115406
[No Abstract] [Full Text] [Related]
10. Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk.
Guo X; Long J; Zeng C; Michailidou K; Ghoussaini M; Bolla MK; Wang Q; Milne RL; Shu XO; Cai Q; Beesley J; Kar SP; Andrulis IL; Anton-Culver H; Arndt V; Beckmann MW; Beeghly-Fadiel A; Benitez J; Blot W; Bogdanova N; Bojesen SE; Brauch H; Brenner H; Brinton L; Broeks A; Brüning T; Burwinkel B; Cai H; Canisius S; Chang-Claude J; Choi JY; Couch FJ; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Droit A; Dörk T; Fasching PA; Fletcher O; Flyger H; Fostira F; Gaborieau V; García-Closas M; Giles GG; Grip M; Guénel P; Haiman CA; Hamann U; Hartman M; Hollestelle A; Hopper JL; Hsiung CN; Ito H; Jakubowska A; Johnson N; Kabisch M; Kang D; Khan S; Knight JA; Kosma VM; Lambrechts D; Le Marchand L; Li J; Lindblom A; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Marme F; Matsuo K; McLean CA; Meindl A; Muir K; Neuhausen SL; Nevanlinna H; Nord S; Olson JE; Orr N; Peterlongo P; Putti TC; Rudolph A; Sangrajrang S; Sawyer EJ; Schmidt MK; Schmutzler RK; Shen CY; Shi J; Shrubsole MJ; Southey MC; Swerdlow A; Teo SH; Thienpont B; Toland AE; Tollenaar RA; Tomlinson IP; Truong T; Tseng CC; van den Ouweland A; Wen W; Winqvist R; Wu A; Yip CH; Zamora MP; Zheng Y; Hall P; Pharoah PD; Simard J; Chenevix-Trench G; ; Dunning AM; Easton DF; Zheng W
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1680-91. PubMed ID: 26354892
[TBL] [Abstract] [Full Text] [Related]
11. Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.
Huisman C; van der Wijst MG; Falahi F; Overkamp J; Karsten G; Terpstra MM; Kok K; van der Zee AG; Schuuring E; Wisman GB; Rots MG
Epigenetics; 2015; 10(5):384-96. PubMed ID: 25830725
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic values of 5-hmC, 5-mC and tet2 in epithelial ovarian cancer.
Zhang LY; Li PL; Wang TZ; Zhang XC
Arch Gynecol Obstet; 2015 Oct; 292(4):891-7. PubMed ID: 25827305
[TBL] [Abstract] [Full Text] [Related]
13. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
